Nehal Jagdish Lakhani MD

PubMed

• A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors.
  Cathy Eng, Nehal J Lakhani, Philip A Philip, Charles Schneider, Benny Johnson
  Targeted Oncology. 2025-03-26
• First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.
  Nehal J Lakhani, Daphne Stewart, Debra L Richardson, Lauren E Dockery, Linda Van Le
  Journal for Immunotherapy of Cancer. 2025-01-11
• First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.
  Nehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson, Haeseong Park, Ding Wang
  Clinical Cancer Research. 2024-12-16

Journal Articles

• Efficacy of Selpercatinib in RET-Altered Thyroid Cancers  
  Lori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine

Abstracts/Posters

• A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
  Nehal Lakhani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018